Integer HoldingsNYSE: ITGR

ITGR's third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.

Integer (ITGR) came out with quarterly earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.27 per share a year ago.

Although the revenue and EPS for Integer (ITGR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.

PLANO, Texas, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on October 1, 2024, and ending at the close of business on December 31, 2024. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company's common stock or a combination thereof, at the Company's election, in respect of the remainder, if any, of the Company's conversion obligation in excess of the aggregate principal amount of the Notes being converted. Any determination regarding the convertibility of the Notes during future periods will be made in accordance with the terms of the Indenture governing the Notes.

Integer Holdings announces to divest its Electrochem business to Ultralife for $50 million in cash.

Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

Integer Holdings announces the completion of its Irish facility expansions in Galway and New Ross to support growth.

ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.